Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

Central Serous Chorioretinopathy Clinical Trial

Official title:

Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05337332
• Other study ID #: RC 7-7-22
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: April 14, 2022
• Est. completion date: June 1, 2023

Study information

• Verified date: April 2022
• Source: Benha University
• Contact: Ahmed Abdelshafy, MD
• Phone: 01222328766
• Email: ahmad4lg[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.

Description:

Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 1, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• patients diagnosed as central serous chorioretinopathy and patients with cystoid macular edema due to irvine-gass syndrome after cataract surgery.

Exclusion Criteria:

• other retinal diseases that may affect CMT and final visual outcome.

• Patients with dense corneal opacity.

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy
• Cystoid Macular Edema
• Irvine-Gass Syndrome
• Macular Edema

Intervention

Drug:
• Triamcinolone Acetonide
Suprachoroidal injection of triamcinolone acetonide

Locations

Country	Name	City	State
Egypt	Ahmed Abdelshafy	Banha	QA

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Intraocular pressure	Changes in intraocular pressure (IOP) measured in millimeter mercury (mmHg) by applanation tonometry.	Baseline and 12 months after injection.
Primary	Central macular thickness	Changes in central macular thickness (CMT) measured in millimeters (mm) by optical coherence tomography (OCT)	Baseline and 12 months after injection.
Secondary	Best corrected visual acuity	Changes in best corrected visual acuity (BCVA) measured in logarithm of minimal angle of resolution (LogMAR) by chart projector.	Baseline and 12 months after injection.